Dual-Targeted Galactose-TPP Dendrimers Modulate Mitochondrial Function and Downstream Outcomes in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) remains therapeutically challenging. Sorafenib, the standard first-line therapy for advanced HCC, suffers from poor aqueous solubility, non-specific biodistribution, dose-limiting toxicities, and the emergence of mitochondrial-mediated resistance. Here, we engineered a dual-targeted den...